AUTHORS
Darina Ocadlikova, MS, Nicola Stefano Fracchiolla, MD2, Federico Lussana, MD, PhD3, Massimiliano Bonifacio, MD4, Lidia Santoro, MD5, Mario Delia, MD6, Sabina Chiaretti, MD7, Crescenza Pasciolla, MD8, Alessandro Cignetti9, Fabio Forghieri, MD10, Francesco Grimaldi, MD11, Nadia Peragine12, Meli Cristian, Biol.Sci13, Ilaria Tanasi14, Claudia Maria Basilico15, Sara Mastaglio, MD16, Cristina Skert, MD17, Anna Rita Guarini18, Robin Foà, MD19, Antonio Curti Sr, MD20
AFFILIATIONS
1 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna, Italy, Bologna, BO, Italy
2 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
3 ASST Papa Giovanni XXIII, Bergamo, Italy, Università Degli Studi Di Milano, Milano, Italy
4 AOUI Verona, Verona, Italy, Università degli Studi di Verona-Silos di Ponente, Verona, Italy
5 Ospedale San Giuseppe Moscati, Avellino, Italy
6 Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy
7 Sapienza University of Rome, Roma, Italy
8 Istituto Tumori Giovanni Paolo II, Bari, Italy
9 Ospedale Mauriziano Umberto I di Torino, Torino, Italy
10 AOU Policlinico di Modena, Modena, Italy, Università degli Studi di Modena e Reggio Emilia, Reggio nell'Emilia, Italy
11 Università degli Studi di Napoli Federico II, Napoli, Italy
12 Sapienza University of Rome, Roma, Italy
13 ASST Papa Giovanni XXIII, Bergamo, Italy
14 AOUI Verona, Verona, Italy, Università degli Studi di Verona-Silos di Ponente, Verona, Italy
15 Ospedale di Circolo e Fondazione Macchi, Varese, Italy
16 San Raffaele Scientific Institute, Milano, Italy
17 Ospedale dell'Angelo, Venezia, Italy
18 Sapienza University of Rome, Roma, Italy
19 Sapienza University of Rome, Roma, Italy, Sapienza University of Rome, Roma, Italy
20 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna, Italy, Bologna, BO, Italy
ABSTRACT
Background. Blinatumomab, a CD19-directed bispecific T-cell engager, has significantly impacted the management and outcome of B-cell acute lymphoblastic leukemia (B-ALL). The immune mechanisms underlying treatment response remain incompletely understood. We previously characterized, for the first time, the immune landscape of paired peripheral blood (PB) and bone marrow (BM) samples from a series of B-ALL patients treated with blinatumomab (Ocadlikova D. et al. Br J Haematol 2023;203:637-650), showing a distinct immune remodeling between the two compartments. Blinatumomab induced a transient redistribution of PB effector T-cell subsets and regulatory T cells (Tregs), a persistent expansion of cytotoxic NK cells, a transient upregulation of immune checkpoint receptors on CD4⁺ and CD8⁺ T cells, an increased CD39 expression on suppressive Tregs, as well as a broader immune remodeling in the BM, including modulation of markers associated with T-cell exhaustion. Here, we have extended the analysis by comparing the immune modulation induced by blinatumomab in relapsed/refractory (R/R) B-ALL and in patients in hematologic remission but with detectable measurable residual disease (MRD).
Methods. The study was carried out on 40 adult B-ALL patients receiving blinatumomab, including both MRD⁺ (n=25) and R/R (n=15) patients. Multiparametric flow cytometry was performed on paired PB and BM samples collected longitudinally before treatment, on day +14 and after the first treatment cycle to characterize immune cell subsets and immune checkpoint expression. Immune profiles were correlated with clinical response.
Results. The expanded analysis refined the previous findings. In particular, cytotoxic NK cells were significantly expanded in PB, while circulating B cells progressively declined and exhibited an increased expression of immune checkpoint molecules in both the PB and BM. HLA-DR expression increased on effector Tregs in the PB, suggesting a sustained activation. TIM-3 expression on BM naïve CD4⁺ T cells was upregulated throughout treatment. Stratification according to disease status revealed distinct compartment-specific immune signatures. While our previous analysis predominantly identified PB changes, the larger cohort allowed to demonstrate a significantly different BM immune modulation in both patient groups. In R/R patients, LAG-3 expression significantly increased on BM CD8⁺ T cells, consistent with an enhanced local T-cell dysfunction. Conversely, MRD⁺ patients displayed a broader immune activation profile characterized by an increased immune checkpoint expression across multiple PB T-cell subsets and B cells, a pattern not observed in R/R patients. Analysis of absolute cell counts further highlighted important biological differences between patients’ groups. Absolute B-cell counts recovered after cycle 1 in MRD+ patients, whereas R/R patients exhibited a persistent B-cell depletion, suggesting profoundly different patterns of immune reconstitution between the two clinical settings. Correlation with the clinical outcome identified immune features associated with response. Responders exhibited higher baseline frequencies of circulating T cells together with a lower expression of immune checkpoint receptors on T-cell subsets compared with non-responders. PD-1 expression on B cells was also reduced in the PB of responders. Responders displayed lower baseline frequencies of BM cytotoxic NK cells.
Conclusions. This extended analysis demonstrates that in B-ALL patients, blinatumomab induces a marked remodeling of the host immune system in both the PB and BM. This refined and broader analysis revealed novel compartment- and disease-specific immune changes and identified baseline immune features associated with clinical response. These findings improve our understanding of blinatumomab-mediated immune modulation and support the development of predictive immune biomarkers in adult B-ALL.
DISCLOSURES
Antonio Curti Sr, MD: AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Honoraria; AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Consultancy (Includes expert testimony)